Bolden Therapeutics

Bolden Therapeutics is driven to improve the lives of those suffering from neurological disease by increasing new brain cell formation from endogenous stem cells, a process called neurogenesis. With neurodegeneration and other diseases, neurogenesis declines, contributing to memory loss and cognitive dysfunction. Thus, Bolden Therapeutics is developing neurogenesis-promoting therapeutics for neurological diseases, including Alzheimer’s and related dementias, Parkinson’s disease, Huntington’s disease, brain injury, stroke, treatment-resistant depression, and cognitive impairments caused by chemotherapy or COVID-19. Scientific Founder, Ashley E Webb, contributes her expertise in neural stem cell homeostasis and cellular mechanisms of aging, while Co-Founder and CEO, Johnny Page, leads their novel compound efforts.

Jobs: